IBDEI10D ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16401,1,4,0)
 ;;=4^N32.81
 ;;^UTILITY(U,$J,358.3,16401,2)
 ;;=^5015652
 ;;^UTILITY(U,$J,358.3,16402,0)
 ;;=Q61.2^^61^772^88
 ;;^UTILITY(U,$J,358.3,16402,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16402,1,3,0)
 ;;=3^Polycystic Kidney,Adult Type
 ;;^UTILITY(U,$J,358.3,16402,1,4,0)
 ;;=4^Q61.2
 ;;^UTILITY(U,$J,358.3,16402,2)
 ;;=^5018796
 ;;^UTILITY(U,$J,358.3,16403,0)
 ;;=N41.1^^61^772^92
 ;;^UTILITY(U,$J,358.3,16403,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16403,1,3,0)
 ;;=3^Prostatitis,Chronic
 ;;^UTILITY(U,$J,358.3,16403,1,4,0)
 ;;=4^N41.1
 ;;^UTILITY(U,$J,358.3,16403,2)
 ;;=^186931
 ;;^UTILITY(U,$J,358.3,16404,0)
 ;;=N11.9^^61^772^100
 ;;^UTILITY(U,$J,358.3,16404,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16404,1,3,0)
 ;;=3^Pyelonephritis,Chronic,Unspec
 ;;^UTILITY(U,$J,358.3,16404,1,4,0)
 ;;=4^N11.9
 ;;^UTILITY(U,$J,358.3,16404,2)
 ;;=^5015574
 ;;^UTILITY(U,$J,358.3,16405,0)
 ;;=N20.9^^61^772^118
 ;;^UTILITY(U,$J,358.3,16405,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16405,1,3,0)
 ;;=3^Urinary Calculus,Unspec
 ;;^UTILITY(U,$J,358.3,16405,1,4,0)
 ;;=4^N20.9
 ;;^UTILITY(U,$J,358.3,16405,2)
 ;;=^5015610
 ;;^UTILITY(U,$J,358.3,16406,0)
 ;;=R97.20^^61^772^31
 ;;^UTILITY(U,$J,358.3,16406,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16406,1,3,0)
 ;;=3^Elevated PSA
 ;;^UTILITY(U,$J,358.3,16406,1,4,0)
 ;;=4^R97.20
 ;;^UTILITY(U,$J,358.3,16406,2)
 ;;=^334262
 ;;^UTILITY(U,$J,358.3,16407,0)
 ;;=N52.36^^61^772^36
 ;;^UTILITY(U,$J,358.3,16407,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16407,1,3,0)
 ;;=3^Erectile Dysfunction After Interstitial Seed Therapy
 ;;^UTILITY(U,$J,358.3,16407,1,4,0)
 ;;=4^N52.36
 ;;^UTILITY(U,$J,358.3,16407,2)
 ;;=^5138933
 ;;^UTILITY(U,$J,358.3,16408,0)
 ;;=N52.37^^61^772^37
 ;;^UTILITY(U,$J,358.3,16408,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16408,1,3,0)
 ;;=3^Erectile Dysfunction After Prostate Ablative Therapy
 ;;^UTILITY(U,$J,358.3,16408,1,4,0)
 ;;=4^N52.37
 ;;^UTILITY(U,$J,358.3,16408,2)
 ;;=^5138934
 ;;^UTILITY(U,$J,358.3,16409,0)
 ;;=N52.35^^61^772^38
 ;;^UTILITY(U,$J,358.3,16409,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16409,1,3,0)
 ;;=3^Erectile Dysfunction After Radiation Therapy
 ;;^UTILITY(U,$J,358.3,16409,1,4,0)
 ;;=4^N52.35
 ;;^UTILITY(U,$J,358.3,16409,2)
 ;;=^5138932
 ;;^UTILITY(U,$J,358.3,16410,0)
 ;;=R31.21^^61^772^58
 ;;^UTILITY(U,$J,358.3,16410,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16410,1,3,0)
 ;;=3^Hematuria,Microscopic,Asymptomatic
 ;;^UTILITY(U,$J,358.3,16410,1,4,0)
 ;;=4^R31.21
 ;;^UTILITY(U,$J,358.3,16410,2)
 ;;=^5139198
 ;;^UTILITY(U,$J,358.3,16411,0)
 ;;=R31.29^^61^772^59
 ;;^UTILITY(U,$J,358.3,16411,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16411,1,3,0)
 ;;=3^Hematuria,Microscopic,Other
 ;;^UTILITY(U,$J,358.3,16411,1,4,0)
 ;;=4^R31.29
 ;;^UTILITY(U,$J,358.3,16411,2)
 ;;=^5019327
 ;;^UTILITY(U,$J,358.3,16412,0)
 ;;=R39.198^^61^772^72
 ;;^UTILITY(U,$J,358.3,16412,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16412,1,3,0)
 ;;=3^Micturition,Oth Difficulties
 ;;^UTILITY(U,$J,358.3,16412,1,4,0)
 ;;=4^R39.198
 ;;^UTILITY(U,$J,358.3,16412,2)
 ;;=^5019347
 ;;^UTILITY(U,$J,358.3,16413,0)
 ;;=R39.191^^61^772^74
 ;;^UTILITY(U,$J,358.3,16413,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16413,1,3,0)
 ;;=3^Need to Immediately Re-Void
 ;;^UTILITY(U,$J,358.3,16413,1,4,0)
 ;;=4^R39.191
 ;;^UTILITY(U,$J,358.3,16413,2)
 ;;=^5139199
